Shao Chang, MD, PhD
Former VP of Clinical Development, BeiGene, previously MedImmune, AstraZeneca, and Eli Lilly
Shao is a seasoned pharmaceutical executive with more than 15 years of experience. Most recently, Shao was Senior Vice President, Head of Clinical Development at BeiGene where he led a global team in three late-phase programs and six early-phase programs. Prior to BeiGene, Shao was Vice President, Global Medical Lead and Clinical Development Lead, Immuno-Oncology at AstraZeneca/MedImmune. Shao spent ten years at Eli Lilly as a Product Team Lead and Clinical Development Lead.
Shao earned his B.S. from Baylor University and completed his MD-PhD program at the University of Texas-Houston (McGovern Medical School). Shao’s hematology and research fellowships were completed at Washington University Medical School.